Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland

Helmut Salzer; Ralf Otto-Knapp; Torsten Bauer; Folke Brinkmann; Cornelia Feiterna-Sperling; Inna Friesen; et al.

doi:10.1159/000539410

Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland

Helmut Salzer
, Ralf Otto-Knapp
, Torsten Bauer
, Folke Brinkmann
, Cornelia Feiterna-Sperling
, Inna Friesen
, et al.

Division of Infectious Diseases and Tropical Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	593-600
Number of pages	8
Journal	Respiration
Volume	103
Issue number	9
DOIs	https://doi.org/10.1159/000539410
Publication status	Published - 01 Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

303031 Tropical medicine
303041 Infectious diseases
302030 Internal medicine

Access to Document

10.1159/000539410

Cite this

@article{16b96fc379964e388cc1ed1d269d99eb,

title = "Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland",

author = "Helmut Salzer and Ralf Otto-Knapp and Torsten Bauer and Folke Brinkmann and Cornelia Feiterna-Sperling and Inna Friesen and \{et al.\}",

year = "2024",

month = sep,

day = "1",

doi = "10.1159/000539410",

language = "English",

volume = "103",

pages = "593--600",

journal = "Respiration",

issn = "1423-0356",

number = "9",

}

TY - JOUR

T1 - Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland

AU - Salzer, Helmut

AU - Otto-Knapp, Ralf

AU - Bauer, Torsten

AU - Brinkmann, Folke

AU - Feiterna-Sperling, Cornelia

AU - Friesen, Inna

AU - et al., null

PY - 2024/9/1

Y1 - 2024/9/1

UR - https://karger.com/res/article/103/9/593/908050/Treatment-of-MDR-Pre-XDR-XDR-and-Rifampicin

UR - https://www.scopus.com/pages/publications/85203303239

U2 - 10.1159/000539410

DO - 10.1159/000539410

M3 - Article

C2 - 38810608

SN - 1423-0356

VL - 103

SP - 593

EP - 600

JO - Respiration

JF - Respiration

IS - 9

ER -

Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland

UN SDGs

Fields of science

Access to Document

Other files and links

Cite this